CD274 and non-small cell lung carcinoma: Similarly, durvalumab, an anti-PD-L1 antibody, prolonged median OS compared with placebo (not reached versus 28.7 months; median follow-up: 25.2 months) in patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy [12].